Methods of making and using racemic and optically pure metabolites of
sibutramine, and pharmaceutically acceptable salts, solvates, and
clathrates thereof, are disclosed. Pharmaceutical compositions and dosage
forms are also disclosed which comprise a dopamine reuptake inhibitor,
such as a racemic or optically pure sibutramine metabolite, and optionally
an additional pharmacologically active compound.
Показаны методы метаболитов делать и использования рацемических и оптически чисто sibutramine, и фармацевтически приемлемо соли, solvates, и клатраты thereof. Фармацевтические составы и формы дозировки также показаны состоят из иа АБС битор reuptake допамина, such as рацемический или оптически чисто метаболит sibutramine, и опционно дополнительной фармакологически активно смеси.
